For research use only. Not for therapeutic Use.
SIRT6-IN-2 (Compound 5) is a selective SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects[1].
Catalog Number | I036314 |
CAS Number | 891002-11-2 |
Synonyms | 5-[[4-(furan-2-carbonylamino)benzoyl]amino]-2-hydroxybenzoic acid |
Molecular Formula | C19H14N2O6 |
Purity | ≥95% |
InChI | InChI=1S/C19H14N2O6/c22-15-8-7-13(10-14(15)19(25)26)21-17(23)11-3-5-12(6-4-11)20-18(24)16-2-1-9-27-16/h1-10,22H,(H,20,24)(H,21,23)(H,25,26) |
InChIKey | WCJCTRHTVZUWSD-UHFFFAOYSA-N |
SMILES | C1=COC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)NC3=CC(=C(C=C3)O)C(=O)O |
Reference | [1]. Damonte P, et al. SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. Bioorg Med Chem. 2017 Oct 15;25(20):5849-5858. |